• Bader Faiyaz Zuberi, Faiza Sadaqat Ali, Tazeen Rasheed, Nimrah Bader, Sana Muhammad Hussain, and Anoshia Saleem.
• Bader Faiyaz Zuberi FCPS, Meritorious Professor, Department of Medicine/Gastroenterology, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
• Pak J Med Sci. 2022 Mar 1; 38 (4Part-II): 965-969.

ObjectivesTo compare the efficacy of Vonoprazan based dual treatment versus PPI based treatment for the eradication of Helicobacter pylori infection.MethodsA randomized controlled trial was conducted in Department of Medicine/Gastroenterology Ruth KM Pfau Civil Hospital, DMC during the period of 22 June to 21 September 2021. Sample size was calculated as 96 in each Group. All patients of age 18-75 years with Helicobacter Pylori Infection were inducted and randomly allocated to two groups. Group-A: were given Capsule Amoxicillin 1 gm; Tablet Clarithromycin 500 mg; Capsule Omeprazole 20 mg all medications were given twice daily for two weeks. Group-B were given Capsule Amoxicillin 1 gm; Tablet Vonoprazan 20 mg (Vonozon©, m/s Getz Pharma, Pakistan) twice daily for two weeks. Confirmation of Hp eradication was done by stool Hp antigen test four weeks after completion of treatment. Nine and four patients were lost to follow-up in Group-A & B respectively. Analysis was conducted on 87 patients in Group-A and 92 patients in Group-B.ResultsOut of eighty-seven patients in Group-A and ninety-two patients in Group-B, 73 (83.9%) patients in Group-A and 86 (93.5%) patients in Group-B had negative H pylori result respectively after treatment (p = .042). Significantly higher frequencies of adverse events were observed in Group-A as compared to Group-B in nausea/vomiting (p = .035) and bloating (p = .045).ConclusionVA-dual provides an acceptable eradication rate with fewer adverse events.Copyright: © Pakistan Journal of Medical Sciences.

5 keywords...

hide…